Correlation Between Spyre Therapeutics and Biocardia

Can any of the company-specific risk be diversified away by investing in both Spyre Therapeutics and Biocardia at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Spyre Therapeutics and Biocardia into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Spyre Therapeutics and Biocardia, you can compare the effects of market volatilities on Spyre Therapeutics and Biocardia and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Spyre Therapeutics with a short position of Biocardia. Check out your portfolio center. Please also check ongoing floating volatility patterns of Spyre Therapeutics and Biocardia.

Diversification Opportunities for Spyre Therapeutics and Biocardia

0.21

Correlation Coefficient

Spyre Therapeutics  Biocardia

Modest diversification

The 3 months correlation between Spyre and Biocardia is 0.21. Overlapping area represents the amount of risk that can be diversified away by holding Spyre Therapeutics and Biocardia in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Biocardia and Spyre Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Spyre Therapeutics are associated (or correlated) with Biocardia. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Biocardia has no effect on the direction of Spyre Therapeutics i.e., Spyre Therapeutics and Biocardia go up and down completely randomly.

Pair Corralation between Spyre Therapeutics and Biocardia

Given the investment horizon of 90 days Spyre Therapeutics is expected to generate 1.53 times more return on investment than Biocardia. However, Spyre Therapeutics is 1.53 times more volatile than Biocardia. It trades about 0.04 of its potential returns per unit of risk. Biocardia is currently generating about -0.02 per unit of risk. If you would invest  1,053  in Spyre Therapeutics on September 21, 2024 and sell it today you would earn a total of  1,260  from holding Spyre Therapeutics or generate 119.66% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Spyre Therapeutics  vs.  Biocardia

Spyre Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spyre Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Biocardia

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biocardia has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Spyre Therapeutics and Biocardia

The main advantage of trading using opposite Spyre Therapeutics and Biocardia positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Spyre Therapeutics position performs unexpectedly, Biocardia can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biocardia will offset losses from the drop in Biocardia's long position.

The idea behind Spyre Therapeutics and Biocardia pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.